Aims/hypothesis. Several effects of thiazolidinediones (TZD) have been shown in adipose tissue but very little is known about the effects in skeletal muscle. We examined the effects of TZD and PPARα ligands on the expression of different genes in L6 muscle cells. Methods. L6 muscle cells were exposed to PPARα and PPARγ ligands for different times. The gene expression of the signalling molecules IRS-1, IRS-2, PKB/Akt, the transcription factor C/EBPα, the uncoupling protein UCP-2 and the adipocyte marker aP2 were measured with real-time PCR. To directly examine the effect of C/EBPα on gene expression, we also transfected L6 cells with this gene. Results. L6 muscle cells showed a low expression of PPARγ 1, no expression of PPARγ 2, and this was not changed by TZD. PPARγ, but not PPARα, ligands rapidly increased the expression of C/EBPα while UCP-2 and in particular the IRS-1 gene was activated with a slow onset (12-24 h). In contrast, neither PKB/Akt nor IRS-2 expression were changed. Transfection with C/EBPα did not increase IRS-1 expression. There was no evidence of transdifferentiation of the muscle to an adipocyte phenotype by TZD since no aP2 expression was found.
dent of PPARγ activation [3] . However, it is still not clear how TZD improve insulin sensitivity.
Activation of PPARγ and its heterodimer partner, RXR leads to the binding of specific DNA sequences; the PPAR response element (PPRE). Very few genes directly involved in insulin signalling and action are known to have PPRE in their promoter region. Using human fat cells and 3T3-L1 adipocytes we recently found [4] that TZD rapidly activated the IRS-2 gene; an important intracellular docking protein for insulinstimulated PI3-kinase activation as well as for betacell growth. However, it has been difficult to clone the entire IRS-2 promoter with the putative PPRE and, thus, we still do not know if the effect of TZD is direct or indirect.
Another important family of transcription factors which is activated by TZD are the CCAAT-box/ enhancer binding proteins (C/EBP). C/EBPα has been Thiazolidinediones (TZD) are a group of recently identified antidiabetic agents that have been shown to improve insulin sensitivity in humans and in animal models of obesity and diabetes [1, 2] . These drugs are high-affinity ligands for the nuclear receptors PPARγ but they also have effects that apparently are indepenshown to be important for the activation of genes and proteins involved in insulin-stimulated glucose transport and GLUT4 translocation [5] . Thus, activation of C/EBPα seems to be a key mechanism through which TZD can enhance insulin action.
It is well-established that the skeletal muscle is the major organ for insulin-stimulated glucose disposal and, thus, it would be logical to believe that the insulin-sensitizing effect of TZD is mainly exerted in the muscles. However, recent studies with lipodystrophic mice have shown that the adipose tissue seems to be critical for this effect of TZD.
Only a few studies have addressed the effect of TZD in vitro in muscle cells. A metabolite of troglitazone was found to enhance total GLUT1 and GLUT4 protein expression in the L6 muscle cell line and also to increase insulin-stimulated glucose uptake [6] . A substantial increase in glucose uptake and GLUT4 translocation in L6 muscle cells after troglitazone exposure has also been reported [7] . Furthermore, using cultured satellite cells from human skeletal muscle it has been found that TZD increases insulin-stimulated PI3-kinase activity associated with IRS-1 [8] .
We examined the effect of PPARα-and PPARγ ligands on the expression of several different genes including some key molecules for insulin's intracellular signalling cascade: PKB/Akt, IRS-1 and IRS-2.
Material and methods
Cell culture. Rat L6 myoblasts, stably transfected with the human insulin receptor (kindly provided by Dr. F. Beguinot, University of Naples) were cultured, differentiated and incubated with various agents during different time periods as indicated in the Results. Except as specified, the cells used for incubations had been differentiated for at least 8 days and had assumed a myotube phenotype. During the incubations, medium and agents were replaced every 24 h.
Protein separation and immunoblotting. Cell lysates and immunoblotting were carried out as described [9] . Antibodies against IRS-1 and IRS-2 (Upstate Biotechnology, Lake Placid, N.Y., USA), PKB/Akt (Biolab, Boston, Mass., USA) and C/EBPα (Santa Cruz Biotechnology, Santa Cruz, Calif.,USA) were used for detection of proteins.
Quantification of the proteins was done by using a densitometer (Molecular Dynamics, Sunnyvale, Calif., USA).
RNA extraction and northern blots. Total cellular RNA was isolated from cells with guanidinium thiocyanate. Northern blot analyses were done on total cellular RNA (25-40 µg) with labelled cDNA probes made against the ribosomal protein 18S as a houskeeping gene and IRS-1, IRS-2 and PKB as previously described [4] .
Nuclear extraction. Briefly, pelleted cells were resuspended in hypotonic buffer containing protease inhibitors and homogenized. Nuclei were collected after centrifugation and resuspended in KCl buffer. The nuclei were allowed to extract under continuous mixing and pelleted by centrifugation. The nuclear extract was dialyzed, precipitated protein and nucleic acids were removed by centrifugation.
Cell transfections. Transient overexpression experiments were done by using a pMEX expression plasmid containing C/EBPα (kind gift from Dr. J. Auwerx, Strasbourg).
Transfection was carried out with the Lipofectamine plus reagent (Life Technologies, Paisley, Scotland) according to the manufacturers instructions.
Quantification using real-time RT-PCR. cDNA was synthesized using Taq Man Reverse Transcription Reagents (Applied Biosystems, Foster City, Calif., USA) according to the manufacturer's instructions. Relative quantification was done by using the ABI Prism 7700 Sequence Detection System with Taq Man sets available upon request. Primers and probes were designed using Primer Express and optimised according to the recommendations in the Taq Man Universal PCR Master Mix protocol (Applied Biosystems). A p value of less than 0.05 was considered statistically significant.
Results
Also in marked contrast to our recent findings in adipocytes [4] , IRS-1 showed a consistent increase in gene expression by both pioglitazone (Fig. 1A ) and rosiglitazone at 1 to 10 µmmol/l but not with the PPARα ligand.
Time-course experiments with northern blots showed no effect on IRS-1 expression after 4, 8 or 12 h of exposure to pioglitazone, but a gradual increase was seen after 24 h, and this was not changed by adding insulin (Fig. 1A) .
The time-course for the increased IRS-1 gene expression in response to pioglitazone using the sensitive Taq Man real-time RT-PCR analysis is shown (Fig. 1B) . A consistent effect of pioglitazone was seen at 24 h and this remained throughout the 72 h observation time while no effect of the PPARα ligand WY was found (Fig. 1B) .
The finding that PPARγ 1 is expressed in L6 cells was also supported by the increased expression of two PPARγ-responsive genes, C/EBPα and UCP-2, following pioglitazone. A more rapid effect was seen for C/EBPα than for IRS-1 or UCP-2 mRNA (Fig. 2A) . The increased C/EBPα expression was sustained throughout the observation time. Since C/EBPα previously has been shown to play a key role for inducing genes associated with an insulin-sensitive cellular phenotype [5, 10] , we transfected the cells with C/EBPα to address the possibility of C/EBPα being a mediator of the TZD effect on IRS-1.
C/EBPα was clearly overexpressed in both cell lysates and nuclear extracts (Fig. 2B) . However, IRS-1 protein expression and mRNA levels were essentially unchanged and the stimulatory effect of pioglitazone was still maintained (Fig. 2C) . The slow time-course for IRS-1 gene activation also suggests that it could be due to an indirect effect on the IRS-1 promoter. This is consistent with the reported sequence of the murine IRS-1 promoter which does not show any typical PPRE (GeneBank accession No. S80679).
One possibility for such a putative effect is that the activation of the IRS-1 gene is not related to PPARγ activation at all, albeit elicited by TZD. It has been shown that some TZD effects are not related to PPARγ activation, such as the anti-inflammatory effects including inhibition of cytokine release [3] .
However, most of our findings are consistent with the concept that the effect of TZD on IRS-1 gene activation is mediated through PPARγ activation. Firstly, we have observed with the sensitive real-time RT-PCR technique that PPARγ 1 is expressed in L6 cells. Secondly, the fact that both pioglitazone and the PPARγ-specific ligand, rosiglitazone but not the selective PPARα ligand, induced IRS-1 gene activation strongly supports the role of PPARγ activation. Thirdly, we found that TZD did increase other PPARγ-responsive genes like UCP-2 and C/EBPα. This effect of pioglitazone to increase C/EBPα expression in L6 myocytes is similar to previous findings in 3T3-L1 adipocytes, although the time-course was more rapid in 3T3-L1 cells [11] .
It is well established that PPARγ activation leads to an increased C/EBPα expression and usually also vice versa since these transcription factors augment the expression of each other. Our data also show that TZD activate C/EBPα expression in L6 myocytes. However, we did not find that C/EBPα activation also increased PPARγ1 expression. This finding is consistent with the recent observation [12] that only the PPARγ 2, and not PPARγ 1, promoter contains functional C/EBP sites increasing the gene expression. An increased PPARγ2 expression would also lead to an adipocyte phenotype, defined as an increased lipid accumulation or aP2 expression, in the muscle cells and this was not seen in the wildtype L6 cells after TZD.
Taken together, our data support the conclusion that TZD increase IRS-1 gene and protein expression through PPARγ activation, possibly as an indirect effect. A likely candidate for such and indirect effect would be C/EBPα which has previously been shown to be important for IRS-1 gene expression. For instance, C/EBPα−/− fibroblasts have low IRS-1 expression which became increased after the cells had been transfected with C/EBPα [10] . The mouse IRS-1 promoter contains several C/EBPα sites and, in addition, C/EBPα has been shown to play a key role for the expression of other important proteins related to insulin action such as GLUT4 [5] .
However, transfecting the cells with C/EBPα, under conditions where C/EBPα was markedly increased in the nuclei, did not increase IRS-1 expression. These data suggest that C/EBPα could be necessary but it is not sufficient to account for the activation of the IRS-1 promoter by TZD. Thus, it is likely that other transcription factors and/or PPARγ co-activators or repressors are necessary for the activation of the IRS-1 promoter by TZD.
In conclusion, we show that TZD increase IRS-1 mRNA and protein in L6 myocytes. This finding might be an important reason for the ability of TZD to increase insulin sensitivity in skeletal muscle. Furthermore, the data clearly show tissue or cell-specific effects of TZD, emphasizing the critical role of tissue or cell-specific transcriptional regulation.
